Discovery Chemistry, Genomics Institute of the Novartis Research Foundation, Metabolism and Pharmacokinetics, San Diego, California 92121.
Discovery Chemistry, Genomics Institute of the Novartis Research Foundation, Metabolism and Pharmacokinetics, San Diego, California 92121.
J Pharm Sci. 2019 Feb;108(2):1053-1060. doi: 10.1016/j.xphs.2018.10.004. Epub 2018 Oct 16.
Accurate determination of the free fraction of a drug in plasma can be challenging when it falls below 1% and even more so when below 0.1%. Equilibrium dialysis with diluted plasma has been used to determine unbound fraction below 1%, but some analytes are not amenable to this method. One robust alternative for accurately measuring very highly bound compounds is equilibrium gel filtration; however, radiolabeled compounds have been used with this technique to quantify the low analyte concentrations. This report examined results obtained using radiolabeled compounds with liquid scintillation detection and those obtained using their nonradiolabeled analogs with liquid chromatography-tandem mass spectrometry detection. The 2 methods provided comparable results over the range of 0.005%-4% free, with a slope of 1.0 and a R = 0.93. These results demonstrate that equilibrium gel filtration with liquid chromatography-tandem mass spectrometry detection can be used earlier in the drug discovery process to determine the unbound fraction of highly bound drugs and may help obviate the need for radiolabeled compound.
当药物在血浆中的游离分数低于 1%时,准确测定就具有挑战性,而当低于 0.1%时则更具挑战性。已经使用稀释血浆的平衡透析来测定低于 1%的未结合分数,但有些分析物不适合这种方法。一种用于准确测量高度结合化合物的强大替代方法是平衡凝胶过滤;然而,已经使用放射性标记化合物和该技术来定量分析低浓度的分析物。本报告检查了使用放射性标记化合物进行液相闪烁检测和使用非放射性标记类似物进行液相色谱-串联质谱检测所获得的结果。在 0.005%-4%游离的范围内,两种方法提供了可比的结果,斜率为 1.0,R = 0.93。这些结果表明,平衡凝胶过滤与液相色谱-串联质谱检测可更早地用于药物发现过程中,以确定高度结合药物的未结合分数,并可能有助于避免对放射性标记化合物的需求。